Outcomes in AML patients receiving HMA + venetoclax combination with prior HMA exposure.

e19011Background: Venetoclax (Ven) is a BCL-2 inhibitor approved in combination with hypomethylating agents (HMAs) in newly diagnosed AML patients who are not candidates for intensive induction bas...